Abstract 116P
Background
Colorectal cancer (CRC) ranks as the second leading cause of mortality, following lung cancer, among cancer-related fatalities in High Income Asia Pacific (HIAP) nations. Despite this, there remains a lack of consistent and comparable data on the burden of CRC in these regions.
Methods
Utilizing tools from the Global Burden of Disease study, we examined CRC's prevalence, incidence, mortality, and disability-adjusted life years (DALYs) by age groups, sex, and years across four HIAP countries from 1990-2019. Moreover, we employed a regression framework model to project CRC-related deaths until 2040.
Results
The aggregate number of prevalent CRC cases surged from 450,169 (95%UI: 433,127-466,354) in 1990 to 1,178,847 (1,026,274-1,347,590) in 2019. During the same period, the death toll increased from 34,338 (32,598-35,179) to 76,929 (64,820-83,603). When considering the annual percentage change (APC), DALYs exhibited a 65% increase from 1990 to 2019. Notably, the age-standardized incidence rate (ASIR) demonstrated a 15% rise in APC, with the most pronounced increases occurring in South Korea (119%), Brunei Darussalam (21%), and Japan (13%). Conversely, Singapore exhibited a 7% decline in ASIR during the same timeframe. In terms of age-standardized mortality rate (ASMR), South Korea reported the highest APC (17%), while Singapore and Japan witnessed declines of 40% and 15%, respectively. The most significant APC in DALYs was noted in Brunei Darussalam (178%), trailed by South Korea (176%), Japan (89%), and Singapore (50%). In 2019, the age group of 85-89 experienced the highest CRC-related deaths, whereas the 75-79 age group exhibited the highest incidence. Meanwhile, the 70-74 age group showed the highest DALYs. Over the past three decades, males carried a greater burden compared to females. By 2040, a projected increase of 73,633 (52,895-102,526) CRC-related deaths is anticipated.
Conclusions
In 2019, CRC contributed to 13.88% of all cancer-related casualties in HIAP nations. The burden of CRC varied persistently among these countries. Nonetheless, it is evident that there is an urgent requirement for the implementation of more effective strategies to mitigate the burden posed by CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract